Compare Incyte Corporation (INCY) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Invesco Solar ETF — how do they compare? Incyte Corporation trades at $112.97 (market cap $22.85B), while Invesco Solar ETF trades at $43.28 (market cap $894.08M). The key difference: Incyte Corporation is far larger — about 25.6× Invesco Solar ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Invesco Solar ETF for 34 Days on average.
| INCY | TAN | |
|---|---|---|
Market Cap | $22.85B | $894.08M |
Volume | 1,927,029 | 370,994 |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $73.95 |
52-Week Low | $83.80 | $43.00 |
Typical Hold Time | 33 Days | 34 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
TAN (Invesco Solar ETF) is trading at $43.53, down 1.96% amid sector-wide pressure from high borrowing costs impacting solar project financing. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from solar industry volatility, price deflation, and margin erosion, having underperformed the S&P 500 by 112% over five years according to Seeking Alpha analysis from August 2026.
Outlook remains challenging with persistent sector headwinds including interest rate sensitivity and market saturation risks. Investment opportunity exists in long-term renewable energy transition, but requires tolerance for high volatility and deeper drawdowns compared to traditional energy ETFs. Key risks include policy uncertainty, grid adaptation costs, and competitive pressure from broader clean energy alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
